Dronedarone: A New Therapeutic Alternative for Cardiac Arrhythmias
1★, 1, 1★ Corresponding author
- 1Department of Pharmacy, Faculty of Technology and Engineering, MS University of Baroda, Kalabhavan, Vadodara – 390001, Gujarat, INDIA.
CORRESPONDENCE
Upaganlawar A
Department of Pharmacy, Faculty of Technology and Engineering, MS University of Baroda, Kalabhavan, Vadodara – 390001, Gujarat, INDIA.
Volume 2, Issue 4 · pp. 430 · 2010 · DOI: 10.4103/0975-1483.71620
ABSTRACT
Sir, As a new therapeutic agent for cardiac arrhythmias, dronedarone (Multaq®), a drug from Sanofi-Aventis, was approved by the FDA on July 2, 2009.[1] It is now available in the market in the form of tablets having 400 mg of the active ingredient. For patients requiring drug therapy or electroshock therapy to retain their normal rhythms, dronedarone is a useful option. However, treatment with dronedarone was associated with an increased likelihood in deaths due to heart failure.[2] Hence, the FDA did not approve dronedarone without a warning for causing deaths in patients with heart failure.[3] Figure 1 shows the structure, the International Union of Pure and Applied Chemists (IUPAC) name, and chemical class of dronedarone.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
A, U., H, G., & R, B. (2010). Dronedarone: A New Therapeutic Alternative for Cardiac Arrhythmias. Journal of Young Pharmacists, 2(4), 430. https://doi.org/10.4103/0975-1483.71620
Copyright and licence
© 2010 Author(s)
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. CC BY-NC-SA 4.0